# Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

> **NCT02264171** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tamsulosin HCl
- **DRUG:** Ketoconazole

## Key facts

- **NCT ID:** NCT02264171
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264171, "Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT02264171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*